Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS207 With or Without JS004 or Docetaxel in Advanced NSCLC
NCT06924606Phase 2Terminated
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Jul 2025
- Primary completion
- Jul 2026
- Modality
- Prophylactic Vaccines, Bispecific Antibodies, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of JS207 in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Shanghai Junshi Biosciences Co., Ltd. Primary endpoint: Objective Response Rate at 1.5 years. Started Jul 2025; status: terminated.
02
Drugs
JS207
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06924606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06924606.